Suvorexant for Sleep Disturbance Shows Promise in Addiction Recovery

For many people navigating recovery from drug or alcohol addiction, suvorexant for sleep disturbance is emerging as a potential tool that clinicians are beginning to take seriously. Sleep problems do not end when substance use stops. Disrupted, restless nights are a recognised feature of withdrawal, and research suggests they drive relapse more significantly than many people realise.

Growing evidence now points to suvorexant, an FDA-approved sleep medication that works differently from traditional sleeping pills, and that may offer real benefits for people in recovery.

Why Sleep Disturbance in Substance Use Recovery Is a Relapse Risk

Sleep problems affect the vast majority of people with substance use disorders (SUDs). Studies estimate that up to 80% of people with alcohol use disorder experience insomnia during withdrawal, and those difficulties frequently persist well beyond the acute phase. Crucially, researchers have found that the severity of sleep disturbances predicts the likelihood of relapse and later substance use.

With alcohol use disorder specifically, untreated insomnia has emerged as a predictor of relapse even months after abstinence. For organisations and clinicians working in this field, that link between poor sleep and relapse is not a detail to overlook. It is a therapeutic target.

Despite this, treatment options have remained limited. Many traditional sleep medications carry their own misuse risks, making them poorly suited for people already vulnerable to addiction. Clinicians have long needed an effective sleep treatment that does not simply exchange one dependency for another.

What Is Suvorexant and How Does It Work?

Suvorexant for sleep works through a mechanism that sets it apart from most other sleep aids. Rather than sedating the brain broadly, it blocks orexin receptors, the brain systems responsible for maintaining active wakefulness. By reducing the “stay awake” signal rather than artificially forcing sedation, suvorexant allows the body to transition into sleep more naturally.

What makes this particularly relevant to addiction medicine is where orexin receptors sit in the brain. These receptors are not only linked to wakefulness. They also connect directly to the brain’s reward and motivation systems, the very circuits that drive craving, drug-seeking behaviour, and the emotional turbulence of withdrawal. Blocking orexin signalling may therefore do more than simply improve sleep. It may address some of the neurological underpinnings of addiction itself.

What Suvorexant for Sleep Reveals in Clinical Research

A landmark clinical trial published in Science Translational Medicine (Huhn et al., 2022) examined suvorexant for sleep disturbance in people with opioid use disorder (OUD). The randomised, double-blind, placebo-controlled trial enrolled 38 participants, all of whom researchers first stabilised on buprenorphine/naloxone before assigning them to receive suvorexant (20 mg or 40 mg) or a placebo. Researchers then gradually reduced buprenorphine/naloxone over four days, followed by a further four days of monitoring.

The findings stood out across several measures.

Sleep improved significantly. Participants receiving suvorexant slept for longer than those on placebo, both during the buprenorphine dose-reduction period and during the monitoring period that followed.

Withdrawal symptoms eased. After buprenorphine/naloxone ended, the suvorexant group reported lower withdrawal severity compared to those receiving placebo.

Craving-related measures shifted positively. During the dose-reduction phase, those taking suvorexant reported reduced opioid “wanting,” a greater desire to avoid opioids, and a stronger sense of self-control over opioid use compared to the placebo group.

Benefits continued after the medication phase ended. Even after buprenorphine/naloxone ended, participants who had taken suvorexant continued to report a higher desire to avoid opioids relative to the placebo group.

No significant misuse risk appeared. Participants did not rate suvorexant highly in terms of subjective “high” or “liking,” and they assigned it a low estimated street value. Researchers found no evidence of dose-dependent increases in misuse potential, and no serious adverse events occurred during the trial.

Why These Findings Matter for Recovery

The trial results carry weight for several reasons. They suggest that suvorexant for sleep in recovery may go beyond simply helping people rest at night. By targeting both the sleep disruption and craving signals tied to opioid withdrawal, the medication could complement existing evidence-based treatments such as buprenorphine.

The apparent absence of misuse potential also matters enormously in this context. One of the central barriers to treating sleep disturbance in substance use recovery has been the risk profile of available medications. If suvorexant can improve sleep without generating new risks, that is clinically significant.

Researchers writing in Neuropsychopharmacology described the orexin system as an “emerging pharmacological target” for sleep disturbance across multiple substance use disorders, noting its role in drug and alcohol-seeking behaviours and emotional symptoms that accompany withdrawal (Gyawali and James, 2023). A separate research group outlined plans for a Phase II trial examining suvorexant specifically for people with alcohol use disorder and co-occurring insomnia, citing the unmet clinical need and the theoretical basis for orexin-targeted treatment in this population (Campbell et al., 2020).

Looking Ahead

The evidence, while promising, is still developing. The key opioid trial enrolled only 38 participants, and researchers need larger, more diverse trials to confirm these findings at scale. Studies into suvorexant for sleep disturbance in alcohol use disorder and other SUDs remain at an earlier stage.

Nevertheless, the direction of travel is encouraging. For the millions of people worldwide who carry the double burden of addiction and chronic sleep problems, treatments that tackle both without compounding risk could make a genuine difference to outcomes.

Sleep has long been an overlooked part of recovery. That is beginning to change.

References

Campbell, E. J., Norman, A., Bonomo, Y., and Lawrence, A. J. (2020). Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial. Brain Research, 1728, 146597. https://doi.org/10.1016/j.brainres.2019.146597

Gyawali, U., and James, M. H. (2023). Sleep disturbance in substance use disorders: The orexin (hypocretin) system as an emerging pharmacological target. Neuropsychopharmacology, 48, 228229. https://doi.org/10.1038/s41386-022-01404-3

Huhn, A. S., Finan, P. H., Gamaldo, C. E., Hammond, A. S., Umbricht, A., Bergeria, C. L., Strain, E. C., and Dunn, K. E. (2022). Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science Translational Medicine, 14(650), eabn8238. https://doi.org/10.1126/scitranslmed.abn8238

Source: addictionpolicy